Quantcast

Latest UCB Inc. Stories

2011-06-09 11:16:00

ATLANTA, June 9, 2011 /PRNewswire/ -- UCB, Inc. today announced an agreement with the U.S. Department of Justice (DOJ) to resolve a previously disclosed government investigation into the marketing and promotion of Keppra®, an anti-epileptic prescription medicine. As previously reported, the issues that were the subject of this investigation occurred more than six years ago, and as recognized by the DOJ, UCB has cooperated fully with the United States since learning of the...

2011-05-31 08:45:00

BALTIMORE, May 31, 2011 /PRNewswire/ -- UCB announced findings of the first cost-effectiveness analysis of Vimpat® (lacosamide) as add-on therapy for adults with uncontrolled partial-onset seizures. The findings were presented at the 16th International Society for Pharmacoeconomics and Outcomes Research (ISPOR) annual meeting in Baltimore, MD, USA. Researchers used a simulated pharmaco-economic model to analyze standard anti-epileptic drug therapy with and without...

2010-11-30 09:00:00

ATLANTA, Nov. 30, 2010 /PRNewswire/ -- New data on UCB's anti-epileptic drug (AED) Vimpat® (lacosamide) C-V will be presented at the 64th annual meeting of the American Epilepsy Society (AES), taking place at the San Antonio Convention Center in San Antonio, Texas from December 3 to 7. Data will also be presented on Keppra XR and the investigative epilepsy therapy, brivaracetam. Vimpat® tablets and injection were launched in the U.S. in May 2009 as an...

2010-11-22 11:03:00

ATLANTA, Nov. 22, 2010 /PRNewswire/ -- New stories and insights from the epilepsy community have been unveiled on EpilepsyAdvocate.com, including new interviews on "Women Succeeding with Epilepsy" and Epilepsy Advocate Radio. These programs represent UCB's continued commitment to the epilepsy community and seek to both empower patients and raise awareness about the condition. NEW WEBISODES FOR WOMEN! Two new video interviews are available featuring Epilepsy Advocates Amy Wyatt and...

2010-11-18 09:00:00

ATLANTA, Nov. 18, 2010 /PRNewswire/ -- UCB, Inc., a global leader in the research and development of medications to treat immunology disorders, today announced the winners of its 2010 UCB Rheumatoid Arthritis Family Scholarship Program for outstanding individuals affected by this condition. UCB is awarding 31 scholarships worth up to $10,000 to help deserving students seek personal growth through higher education. The scholarship winners include rheumatoid arthritis (RA) patients, as...


Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'